Reformation Inc.
REF
NYSE
Upcoming IPOs
Expected Listing Date: 2026-07-30
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-
-
-
886.14M~1.00B
-
2026-06-25
Public Filing
View Prospectus
Pending
Offering
Price Range: 15.00~17.00
Shares to be Issued: 14.06M
2026-07-29
Offering End Date
Offering Price: Pending
Post IPO Outstanding: 59.08M
2026-07-30
Listed
No Data
About REF
Scribe Therapeutics Inc. is a clinical-stage biotechnology company based in Alameda, California, founded in 2017 and co-founded by Nobel laureate Jennifer Doudna. It develops in vivo CRISPR therapeutics for cardiovascular diseases, using a novel CasX enzyme. Its platforms include X-Editor for gene editing and ELXR for epigenetic silencing without DNA cutting. Lead candidate STX-1150 targets PCSK9 to lower LDL-C and is in a Phase 1 trial in Australia, with initial data expected in H1 2027. Preclinical programs STX-1200 (Lp(a)) and STX-1400 (APOC3) are supported by over $25 million in CIRM grant funding.

Webull offers Reformation Inc. stock information, including NYSE: REF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading REF stock methods without spending real money on the virtual paper trading platform.